What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study, Animal Study).

Reprogramming CD8+ T-cell branched N-glycosylation limits exhaustion, enhancing cytotoxicity and tumor killing

View Full Paper

Ask AI

Bookmark

Authors

Research shows that altering N-glycosylation in CD8+ T cells improves tumor killing, suggesting new strategies in cancer therapy.

Improved cytotoxicity observed in CD8+ T cells lacking mgat5 gene, enhancing their tumor-killing ability.
CD8+ T cells with β1,6-GlcNAc branched N-glycans exhibited increased exhaustion markers like PD1 and Tim3.
Study utilized CRISPR/Cas9 to delete mgat5, revealing its pivotal role in T-cell function and exhaustion.
Research supports that targeting n-glycosylation could enhance both native and car t cell therapies in solid tumors.

Azevedo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Research shows that altering N-glycosylation in CD8+ T cells improves tumor killing, suggesting new strategies in cancer therapy.

Improved cytotoxicity observed in CD8+ T cells lacking mgat5 gene, enhancing their tumor-killing ability.
CD8+ T cells with β1,6-GlcNAc branched N-glycans exhibited increased exhaustion markers like PD1 and Tim3.
Study utilized CRISPR/Cas9 to delete mgat5, revealing its pivotal role in T-cell function and exhaustion.
Research supports that targeting n-glycosylation could enhance both native and car t cell therapies in solid tumors.

Azevedo et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark